Study guide

10.2 Depression, Anxiety & Psychosis

APC Intern Written Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Pathway to General Registration 1.3 Restricted Open-Book Strategy (AMH & APF) 1.4 Scoring, Results & Appeals

2 Legal Framework: PBS & Medicine Schedules

2.1 PBS, Authority Prescriptions & Special Access Scheme 2.2 Schedules 2 & 3 (Pharmacy & Pharmacist Only Medicines) 2.3 Schedules 4 & 8 (Prescription Only & Controlled Drugs)

3 Legal Framework: Privacy, National Law & Pharmacy Board

3.1 Privacy, Confidentiality & Patient Rights 3.2 Health Practitioner National Law & Registration 3.3 Pharmacy Board Codes, Guidelines & Standards

4 Patient-Centred Medication Management

4.1 Assessing Clinical Situations & Treatment Options 4.2 Patient Factors: Adherence, Efficacy & Safety 4.3 Drug & Dosage-Form Factors 4.4 Culturally Responsive Medication Management

5 Primary Care & Judicious Use of Medicines

5.1 Primary Care & OTC Assessment 5.2 Judicious Use of Antimicrobials & High-Risk Agents 5.3 Non-Pharmacological Options & Evidence-Based OTC Choices

6 Dispensing & Clinical Appropriateness

6.1 Prescription Evaluation 6.2 Clinical Appropriateness Checks 6.3 Labelling, Packaging & Dispensing Standards 6.4 Communicating with Prescribers & Documenting Changes

7 Counselling & Acute Care

7.1 Patient-Centred Counselling 7.2 Confirming Understanding & Lifestyle Counselling 7.3 Acute Illness, Injury & Emergency Response

8 Therapeutics: Cardiovascular & Endocrine

8.1 Hypertension & Heart Failure 8.2 Ischaemic Heart Disease & Anticoagulation 8.3 Diabetes Medicines 8.4 Thyroid & Lipid Disorders

9 Therapeutics: Infection, Respiratory & Gastrointestinal

9.1 Anti-Infectives & Infection Management 9.2 Asthma & COPD 9.3 Gastrointestinal & Hepatic Conditions 9.4 Vaccination & Travel Health

10 Therapeutics: Neurology, Psychiatry & Pain

10.1 Epilepsy & Movement Disorders 10.2 Depression, Anxiety & Psychosis 10.3 Pain Management & Opioids 10.4 Migraine & Common Analgesics

11 Therapeutics: Special Populations & Systems

11.1 Women's Health, Contraception & Pregnancy 11.2 Dermatology, Ophthalmology & ENT 11.3 Renal/Hepatic Impairment & Dose Adjustment

12 Therapeutics: Rheumatology, Haematology, Urology, Oncology & Toxicology

12.1 Rheumatology: Gout, Osteoarthritis & Inflammatory Arthritis 12.2 Haematology: Anaemias & Blood Safety Monitoring 12.3 Urology & Men's Health 12.4 Oncology Support & Oral Anticancer Medicines 12.5 Toxicology & Poisoning Management

13 Monitoring: Clinical Review

13.1 Clinical Review Process 13.2 Interpreting Laboratory & Clinical Monitoring 13.3 Recommending Treatment Modifications

14 Monitoring: Safety & Adverse Drug Reactions

14.1 Adverse Drug Reactions & Reporting 14.2 Allergies, Sensitivities & Cross-Reactivity 14.3 High-Risk Medicines Monitoring

15 Compounding Medicines

15.1 Determining Required Formulations 15.2 Compounding Standards & Quality 15.3 Patient-Specific Preparations

16 Pharmaceutical Calculations

16.1 Dosage Calculations 16.2 Concentrations, Dilutions & Alligation 16.3 Half-Life & Basic Kinetic Calculations

17 Promote Health & Well-Being

17.1 National & Local Health Priorities 17.2 Screening Programs & Pharmacist Role 17.3 Culturally Responsive Promotion & Self-Sufficiency

10.2 Depression, Anxiety & Psychosis

Key Takeaways Explain This Topic AI

SSRIs and SNRIs have a delayed therapeutic onset (often weeks); counsel expectations and monitor early for worsening mood, agitation, and suicide risk — especially in young people.

Serotonin syndrome is a medical emergency: recognise the triad of neuromuscular, autonomic and mental-status changes when serotonergic agents are combined or overdosed.

Benzodiazepines are for short-term or intermittent use where indicated; dependence, falls, cognitive impairment and withdrawal risk rise with prolonged use.

Antipsychotics require metabolic monitoring (weight, glucose/HbA1c, lipids, blood pressure) and vigilance for extrapyramidal effects; clozapine has additional intensive monitoring (outside routine exam detail but concept of special status).

Lithium needs serum level, renal and thyroid monitoring concepts; St John’s wort induces CYP3A4/P-gp and reduces efficacy of many medicines including oral contraceptives and some antidepressants — do not combine casually with serotonergic drugs.

Last updated: August 2026

10.2 Depression, Anxiety & Psychosis

Quick Answer: SSRIs/SNRIs take weeks for full effect — counsel persistence, and monitor early for agitation, worsening mood and suicide risk (especially young people). Know serotonin syndrome red flags with serotonergic combinations. Benzodiazepines are short-term tools with dependence risk. Antipsychotics need metabolic monitoring . Lithium needs levels + renal + thyroid concepts. St John’s wort is a major inducer/interactor , not a harmless tea.

Mental health medicines are high-volume community supplies and high-stakes exam content under 3.1–3.3 : assess the person, implement a safe plan, and monitor for efficacy and harm. Use non-judgemental communication; stigma reduces adherence and disclosure of suicidal thoughts.

Depression and anxiety — SSRI and SNRI foundations

Selective serotonin reuptake inhibitors (SSRIs) (e.g. sertraline, escitalopram, fluoxetine, citalopram, paroxetine) and serotonin–noradrenaline reuptake inhibitors (SNRIs) (e.g. venlafaxine, desvenlafaxine, duloxetine) are first-line pharmacological options for many people with major depression and for several anxiety disorders, alongside psychological therapies.

Onset delay — set expectations

Therapeutic benefit is often delayed 2–4 weeks (sometimes longer for full response), while early adverse effects (nausea, headache, sleep change, anxiety surge, sexual dysfunction) can appear within days. Exam-critical counselling:

Do not stop after a few days because “it isn’t working yet”.

Some people feel more anxious or activated early — contact the prescriber if severe.

Nausea often settles; taking with food may help for some agents (check product advice).

Sexual dysfunction is common and under-reported — invite open discussion; do not dismiss.

Discontinuation symptoms can occur if stopped abruptly (especially shorter half-life agents such as paroxetine or venlafaxine) — taper under medical advice.

Suicide risk monitoring early in treatment

Antidepressants can be associated with increased suicidal thinking and behaviour early in treatment , particularly in children, adolescents and young adults . Pharmacists should:

Ask about mood change, agitation, restlessness, or new suicidal thoughts at initiation and early supply.

Encourage involvement of trusted supports where appropriate and consented.

Ensure the patient knows how to access urgent help (GP, crisis services, emergency department).

Never trivialise statements of hopelessness; escalate appropriately while respecting privacy frameworks.

This is not a reason to refuse all antidepressants; it is a reason for informed monitoring and safety-netting.

Other practical SSRI/SNRI points

  • Issue High-yield note
  • Bleeding risk SSRIs may increase bleeding tendency, especially with NSAIDs, antiplatelets, anticoagulants
  • Hyponatraemia Risk higher in older people; consider if confusion or falls after initiation
  • QT prolongation Particular caution with some agents (e.g. citalopram dose limits) and interacting drugs
  • Dose forms Controlled-release products must not be crushed casually
  • Pregnancy / breastfeeding Individualised risk–benefit with prescriber; do not stop abruptly without advice
  • Serotonin syndrome — recognise and act

Serotonin syndrome is a potentially life-threatening excess of serotonergic activity. Risk rises with combinations (e.g. SSRI + MAOI — contraindicated patterns; SSRI + tramadol; SSRI + triptan in some contexts; SSRI + St John’s wort; overdose).

Clinical pattern (conceptual triad):

  • Mental status — agitation, confusion, restlessness
  • Autonomic — sweating, tachycardia, hypertension/lability, hyperthermia, diarrhoea
  • Neuromuscular — tremor, hyperreflexia, clonus, rigidity

Pharmacy action: treat as urgent medical emergency if suspected; stop further serotonergic doses pending medical assessment; document interacting medicines carefully when reviewing new prescriptions.

Benzodiazepines — short-term use and dependence

Benzodiazepines (e.g. diazepam, temazepam, oxazepam, alprazolam, clonazepam) enhance GABA activity and are used for acute anxiety, alcohol withdrawal (specialist pathways), seizures, and short-term insomnia in selected cases.

Core principles for Australian community pharmacy:

Prefer lowest effective dose and shortest duration consistent with the indication.

Dependence , tolerance, and withdrawal (including rebound anxiety/insomnia, and rarely seizures with abrupt stop after prolonged use) are real risks.

Adverse effects: sedation, falls (especially older adults), cognitive impairment, driving impairment, and respiratory depression risk with opioids/alcohol.

S4 medicines with prescription requirements; some jurisdictions have additional real-time prescription monitoring considerations for high-risk combinations.

Non-drug strategies (sleep hygiene, CBT for insomnia/anxiety) should be reinforced where appropriate.

Exam distractors often suggest long-term “as needed forever” benzodiazepines as first-line chronic anxiety care — that is usually the wrong framing when psychological therapy and SSRI/SNRI strategies are more appropriate long-term options.

Psychosis and antipsychotics — metabolic monitoring

Antipsychotics treat schizophrenia spectrum disorders, acute psychosis, bipolar mania (selected agents), and sometimes off-label behavioural symptoms (specialist caution). They divide broadly into first-generation (typical) and second-generation (atypical) agents, with overlapping risks.

Metabolic syndrome risk

Many second-generation agents (e.g. olanzapine, quetiapine, clozapine — special status) promote weight gain, dyslipidaemia, and insulin resistance . Pharmacy role:

Support baseline and periodic monitoring concepts: weight/BMI, waist, blood pressure, fasting glucose or HbA1c, lipids (local protocols and AMH).

Counsel lifestyle: diet, activity, smoking cessation support.

Flag rapid weight gain early to the prescriber — do not wait for frank diabetes.

Other antipsychotic safety themes

Effect Notes

Extrapyramidal symptoms (EPS) Dystonia, parkinsonism, akathisia — more classic with high-potency first-generation agents

  • Tardive dyskinesia Long-term risk; report abnormal movements
  • Hyperprolactinaemia Sexual dysfunction, menstrual change, galactorrhoea
  • Sedation / orthostasis Falls risk; caution with other CNS depressants
  • QT prolongation Selected agents and combinations
  • Neuroleptic malignant syndrome Rare emergency: rigidity, fever, autonomic instability

Clozapine has intensive blood monitoring for agranulocytosis and other special requirements — exam items usually test that it is not a routine unsupervised community initiation, not detailed titration tables.

Lithium — monitoring concepts

Lithium is a highly effective mood stabiliser for bipolar disorder with a narrow therapeutic index .

Monitoring pillars (concepts, exact target ranges from AMH/local lab):

  • Serum lithium levels — trough timing relative to dose; interpret with clinical status
  • Renal function — lithium can impair kidneys long-term; dehydration raises levels
  • Thyroid function — hypothyroidism risk
  • Electrolytes / calcium as indicated

Toxicity clues: coarse tremor, diarrhoea, vomiting, ataxia, confusion, severe drowsiness. Precipitants include dehydration , NSAID use, ACE inhibitors/ARBs, thiazides, low-salt diets, and acute illness. Counsel patients to maintain fluid intake, seek advice before new OTC NSAIDs, and not double doses after missed tablets without advice.

St John’s wort and complementary serotonergic products

St John’s wort ( Hypericum perforatum ) induces CYP3A4 and P-glycoprotein , reducing concentrations of many medicines (e.g. some oral contraceptives → pregnancy risk, some immunosuppressants, some antiretrovirals, warfarin variability, certain anticancer agents). It also has serotonergic activity and can contribute to serotonin syndrome with antidepressants.

Pharmacy exam stance:

Ask about complementary medicines routinely.

Do not recommend St John’s wort as a casual add-on to prescription antidepressants.

Warn that “natural” does not mean interaction-free.

Integrated counselling approach

Mental health supply is more than handing over a box. Confirm the patient knows what the medicine is for , when benefit is expected , what adverse effects to report , how long to continue , and who to contact if mood worsens . Document interventions and collaborate with GPs, psychiatrists, and mental health services within privacy rules. For Intern Written items, the highest-scoring answers combine empathy , pharmacology , and safety monitoring rather than pure drug-name recall.